The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Open accessAbstract
BACKGROUND In the preplanned interim analysis of the TOPAZ-1 study, durvalumab plus gemcitabine-cisplatin significantly improved overall survival versus placebo plus gemcitabine-cisplatin in participants with advanced biliary tract cancer. We aimed to report updated overall survival and safety data from TOPAZ-1 with additional follow-up and data maturity beyond the interim analysis. METHODS TOPAZ-1 was a phase 3, randomised, double-masked, placebo-controlled, global study done at 105 sites in 17 countries. Participants aged 18 years or older with unresectable, locally advanced, or metastatic biliary tract cancer were randomly assigned (1:1) to durvalumab plus gemcitabine-cisplatin or placebo plus gemcitabine-cisplatin using a computer-generated randomisation scheme, stratified by disease status and primary tumour location. Participants received durvalumab (1500 mg) or placebo on day 1 of each cycle every 3 weeks for up to eight cycles, plus gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) intravenously on days 1 and 8 of each cycle every 3 weeks for up to eight cycles, followed by durvalumab (1500 mg) or placebo monotherapy every 4 weeks until disease progression or other discontinuation criteria were met. Investigators and participants were masked to study treatment. The primary endpoint was overall survival. TOPAZ-1 met its primary endpoint at the preplanned interim analysis, and the study is active but no longer recruiting participants. Updated overall survival and safety data from TOPAZ-1, with additional follow-up (data cutoff Feb 25, 2022) and data maturity beyond the interim analysis, are reported here. Efficacy was assessed in the full analysis set (all randomly assigned participants). Safety was assessed in the safety analysis set (all participants who received at least one dose of study treatment). The TOPAZ-1 study is registered with ClinicalTrials.gov, NCT03875235. FINDINGS From April 16, 2019, to Dec 11, 2020, 914 participants were enrolled, 685 of whom were randomly assigned (341 to the durvalumab plus gemcitabine-cisplatin group and 344 to the placebo plus gemcitabine-cisplatin group). 345 (50%) participants were male and 340 (50%) were female. Median follow-up at the updated data cutoff was 23·4 months (95% CI 20·6-25·2) in the durvalumab plus gemcitabine-cisplatin group and 22·4 months (21·4-23·8) in the placebo plus gemcitabine-cisplatin group. At the updated data cutoff, 248 (73%) participants in the durvalumab plus gemcitabine-cisplatin group and 279 (81%) participants in the placebo plus gemcitabine-cisplatin group had died (median overall survival 12·9 months [95% CI 11·6-14·1] vs 11·3 months [10·1-12·5]; hazard ratio 0·76 [95% CI 0·64-0·91]). Kaplan-Meier-estimated 24-month overall survival rates were 23·6% (95% CI 18·7-28·9) in the durvalumab plus gemcitabine-cisplatin group and 11·5% (7·6-16·2) in the placebo plus gemcitabine-cisplatin group. Maximum grade 3 or 4 adverse events occurred in 250 (74%) of 338 participants in the durvalumab plus gemcitabine-cisplatin group and 257 (75%) of 342 in the placebo plus gemcitabine-cisplatin group. The most common maximum grade 3 or 4 treatment-related adverse events were decreased neutrophil count (70 [21%] vs 86 [25%]), anaemia (64 [19%] vs 64 [19%]), and neutropenia (63 [19%] vs 68 [20%]). INTERPRETATION Durvalumab plus gemcitabine-cisplatin showed robust and sustained overall survival benefit with no new safety signals. Findings continue to support the regimen as a standard of care for people with untreated, advanced biliary tract cancer. FUNDING AstraZeneca.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Self-citationDurvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Oh, D.-Y., Ruth He, A., Qin, S., Chen, L.-T., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Ah Lee, M., Kitano, M., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200015 · Cited by 1,217
Self-citationKelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00727-4 · Cited by 1,169
Self-citationValle, J. W., Kelley, R. K., Nervi, B., Oh, D.-Y., & Zhu, A. X. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00153-7 · Cited by 1,043
Self-citationLepage, C., Capocaccia, R., Hackl, M., Lemmens, V., Molina‐Montes, E., Pierannunzio, D., Sant, M., Trama, A., Faivre, J., Hackl, M., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.034 · Cited by 149
Rimini, M., Fornaro, L., Lonardi, S., Niger, M., Lavacchi, D., Pressiani, T., Lucchetti, J., Giordano, G., Pretta, A., Tamburini, E., et al. (2023) · Liver International · doi:10.1111/liv.15641 · Cited by 117
Ahn, D. H., & Bekaii‐Saab, T. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.10.01 · Cited by 63
Quality of Life and Symptom Management in Advanced Biliary Tract Cancers
Hunter, L. A., & Soares, H. P. (2021) · Cancers · doi:10.3390/cancers13205074 · Cited by 36
Hyung, J., Kim, B. J., Yoo, C., Kim, K.-P., Jeong, J. H., Chang, H.-M., & Ryoo, B. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.326 · Cited by 32
Cited by
Hong, L., Mei, J., Sun, X., Wu, Y., Dong, Z., Jin, Y., Gao, L., Cheng, J., Tian, W., Liu, C., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001283 · Cited by 42
Self-citation
Metadata
- Authors
- Oh, D.-Y., He, A. R., Bouattour, M., Okusaka, T., Qin, S., Chen, L.-T., Kitano, M., Lee, C.-K., Kim, J. W., Chen, M.-H., Suksombooncharoen, T., Ikeda, M., Lee, M. A., Chen, J.-S., Potemski, P., Burris, H. A., Ostwal, V., Tanasanvimon, S., Morizane, C., Zaucha, R. E., McNamara, M. G., Avallone, A., Cundom, J. E., Breder, V., Tan, B., Shimizu, S., Tougeron, D., Evesque, L., Petrova, M., Zhen, D. B., Gillmore, R., Gupta, V. G., Dayyani, F., Park, J. O., Buchschacher, G. L., Rey, F., Kim, H., Wang, J., Morgan, C., Rokutanda, N., Żotkiewicz, M., Vogel, A., & Valle, J. W.
- Venue
- The Lancet Gastroenterology & Hepatology
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 9
- Issue
- 8
- Pages
- 694-704
- ISSN
- 2468-1156 (ISSN-L)
- 2468-1253
- OpenAlex
- W4399119041
- Cited by
- 308
- References
- 9
- FWCI
- 117.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. https://app.cochat.ai/papers/10.1016/s2468-1253(24)00095-5
- The paper
- Oh, D.-Y., He, A. R., Bouattour, M., Okusaka, T., Qin, S., Chen, L.-T., Kitano, M., Lee, C.-K., Kim, J. W., Chen, M.-H., Suksombooncharoen, T., Ikeda, M., Lee, M. A., Chen, J.-S., Potemski, P., Burris, H. A., Ostwal, V., Tanasanvimon, S., Morizane, C., . . . Valle, J. W. (2024). Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(24)00095-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.